All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort studyMichael Manns, Stephanie Noviello, Stuart C. Gordon et al.|The Lancet|2014Cited by 343
O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTSM.P. Manns, Stephanie Noviello, S. Pol et al.|Journal of Hepatology|2014Cited by 20